Company Performance Metrics
- Alex Babayan: Vice President of Regulatory Affairs
- Pin Wang: Founder
Appia Bio is a biotechnology company that focuses on the research and development of off-the-shelf allogeneic cell therapies. It works on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. With its ACUA (Appia Cells Utilized for
Allogeneic) technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs).
